Focused On-demand Library for Dolichol-phosphate mannosyltransferase subunit 3

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.

Several key aspects differentiate our library:

Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

Q9P2X0

UPID:

DPM3_HUMAN

Alternative names:

Dolichol-phosphate mannose synthase subunit 3; Dolichyl-phosphate beta-D-mannosyltransferase subunit 3; Mannose-P-dolichol synthase subunit 3; Prostin-1

Alternative UPACC:

Q9P2X0; Q5SR62; Q5SR63; Q9BXN4; Q9BXN5

Background:

Dolichol-phosphate mannosyltransferase subunit 3, also known as Dolichol-phosphate mannose synthase subunit 3, plays a crucial role as a stabilizer in the dolichol-phosphate mannose (DPM) synthase complex. This protein is pivotal in tethering the catalytic subunit DPM1 to the endoplasmic reticulum, a key step in glycosylation processes.

Therapeutic significance:

The protein is linked to Muscular dystrophy-dystroglycanopathy congenital with impaired intellectual development B15 and Muscular dystrophy-dystroglycanopathy limb-girdle C15, diseases characterized by muscle weakness and developmental challenges. Understanding its role could lead to novel therapeutic strategies targeting these muscular dystrophies.